Kaufman joins AccuImage
MRI pioneer Leon Kaufman, Ph.D., has taken the helm of AccuImage Diagnostics. Kaufman joined the company as CEO in mid-February, leaving Toshiba amid that company's reorganization (SCAN 1/31/01). Kaufman in 1975 established one of the world's first MRI
MRI pioneer Leon Kaufman, Ph.D., has taken the helm of AccuImage Diagnostics. Kaufman joined the company as CEO in mid-February, leaving Toshiba amid that company's reorganization (SCAN 1/31/01). Kaufman in 1975 established one of the world's first MRI development programs at the University of California, San Francisco, a program successively supported by Pfizer, Diasonics, and Toshiba America, as well as the National Institutes of Health. After leaving UCSF in 1994, Kaufman spent six years as Toshiba's chief scientist and vice president of engineering. In his new position at AccuImage, Kaufman will focus on the development and marketing of 3-D visualization and networking technology.
2/28/01, Issue # 1504, page 4.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
